International Journal of Clinical Research

Objective To analyze the value of sacubitril/valsartan combined with dapagliflozin in the treatment of heart failure with reduced ejection fraction. Methods A total of 126 patients with heart failure due to reduced ejection fraction admitted to our hospital were selected. The research period was from February 2024 to March 2025. Sixty-three cases were selected for treatment with sacubitril/valsartan alone (control group), and another 63 cases were treated with dapagliflozin in combination (observation group). Observe the therapeutic effects of single treatment and combined treatment, and compare the differences between the two therapies in cardiac function levels such as left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular ejection fraction (LVEF), and quality of life. Record the impact of different therapies on their adverse reactions. Results The total effective rate was 98.41% (62/63) in the observation group and 85.71% (54/63) in the control group, with a significant difference (P<0.05). Before treatment, there was no significant difference in cardiac function levels and quality of life scores between the two groups before treatment (P>0.05).; After treatment, the LVESD, LVEF and quality of life scores in the observation group all increased significantly, and the LVEDD index level was lower than that in the control group. There were significant differences in cardiac function and quality of life between the groups (P<0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group (4.76%vs12.70%), and the difference was significant (P<0.05). Conclusion For patients with heart failure due to reduced ejection fraction, the implementation of sacubitril/valsartan combined with dapagliflozin has obvious advantages in terms of therapeutic effect, improvement of cardiac function, and reduction of adverse reactions. It is recommended for clinical promotion and application.

Heart failure due to reduced ejection fraction; Sacubitril/valsartan; Dapagliflozin; Therapeutic effect